COVID-19特輯

冠狀病毒，2020. 由David S. Goodsell @ RCSB PDB原圖修改

最近爆發的新型冠狀病毒傳染病（Novel Coronavirus disease 2019: COVID-19）對全世界的人們都構成了嚴重威脅。為了儘早了解新病毒（Severe Acute Respiratory Syndrome Coronavirus 2: SARS-CoV-2）以開發出有效的抗病毒藥物，已經有很多科研人員開始了相關蛋白結構的研究，並且將所獲得結構數據存儲與PDB。 PDBj為用戶提供了COVID-19相關數據一覽的門戶頁面，並將於每週三更新當日新發佈的相關數據。

有關該病毒蛋白質的解說，請參見下面的“當月的分子”頁面。

“所有結構”標籤的頁面則逐一羅列了所有的數據，包括由同一研究組提交的系列數據群。 “代表性結構”標籤的頁面精選具有相同胺基酸序列的結構數據中的高分辨率數據，不重複選擇具有同一胺基酸序列的數據，即使該數據可能包含不同的配體。 “最新條目”標籤內包含本週新更新數據。

Created: 2020-09-03 (last edited: more than 1 year ago)

所有結構 (5197)代表性結構 (2266)最新條目 (44)

8UE0

Crystal structure of SARS-CoV-2 3CL protease with inhibitor 47
Descriptor:	2,4-dichloro-Nalpha-[(2R)-2-chloro-3-(2-cyanophenyl)propanoyl]-N-[(2S)-4-{[4-(dimethylamino)butyl]amino}-1-(4-fluorophenyl)-4-oxobutan-2-yl]-D-phenylalaninamide, 3C-like proteinase nsp5, CHLORIDE ION, ...
Authors:	Forouhar, F, Liu, H, Zack, A, Iketani, S, Williams, A, Vaz, D.R, Habashi, D.L, Choi, K, Resnick, S.J, Chavez, A, Ho, D.D, Stockwell, B.R.
Deposit date:	2023-09-29
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (2.16 Å)
Cite:	Development of small molecule non-covalent coronavirus 3CL protease inhibitors from DNA-encoded chemical library screening. Nat Commun, 16, 2025

8YDP

Crystal structure of the receptor binding domain of SARS-CoV-2 spike protein in complex with Ce9
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, SARS-CoV-2 inhibiting peptide Ce9, ...
Authors:	Nakamura, S, Numoto, N, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (2.3 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDQ

Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BA.2 variant spike protein in complex with Ce149
Descriptor:	GLYCEROL, SARS-CoV-2 inhibiting peptide Ce149, Spike protein S1
Authors:	Nakamura, S, Numoto, N, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (1.9 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDR

Crystal structure of the receptor binding domain of SARS-CoV-2 Alpha variant spike protein in complex with Ce59
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, SARS-CoV-2 inhibiting peptide Ce59, Spike protein S1
Authors:	Nakamura, S, Numoto, N, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (2.3 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDS

Crystal structure of the receptor binding domain of SARS-CoV-2 Delta variant spike protein in complex with Ce59
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, GLYCEROL, SARS-CoV-2 inhibiting peptide Ce59, ...
Authors:	Nakamura, S, Numoto, N, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (1.9 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDT

Crystal structure of the receptor binding domain of SARS-CoV-2 Alpha variant spike protein in complex with Ce41
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, SARS-CoV-2 inhibiting peptide Ce41, Spike protein S1
Authors:	Nakamura, S, Numoto, N, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (2.5 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDU

Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BA.2 variant spike protein in complex with CeSPIACE
Descriptor:	GLYCEROL, SARS-CoV-2 inhibiting peptide CeSPIACE, Spike protein S1
Authors:	Nakamura, S, Numoto, N, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (1.7 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDV

Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron BA.5 variant spike protein in complex with CeSPIACE
Descriptor:	GLYCEROL, SARS-CoV-2 inhibiting peptide CeSPIACE, Spike protein S1
Authors:	Nakamura, S, Numoto, N, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (2.2 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDW

Crystal structure of the receptor binding domain of SARS-CoV-2 Omicron XBB.1.5 variant spike protein in complex with CeSPIACE
Descriptor:	GLYCEROL, SARS-CoV-2 inhibiting peptide CeSPIACE, SODIUM ION, ...
Authors:	Nakamura, S, Numoto, N, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (2 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDX

Cryo-EM structure of SARS-CoV-2 spike ectodomain (HexaPro, Omicron BA.2 variant) in complex with CeSPIACE
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, CeSPIACE, Spike glycoprotein
Authors:	Suzuki, H, Nakamura, S, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	ELECTRON MICROSCOPY (4.9 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDY

Cryo-EM structure of SARS-CoV-2 spike ectodomain (HexaPro, Omicron BA.5 variant) in complex with CeSPIACE, class 1
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, CeSPIACE, Spike glycoprotein
Authors:	Suzuki, H, Nakamura, S, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	ELECTRON MICROSCOPY (8 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

8YDZ

Cryo-EM structure of SARS-CoV-2 spike ectodomain (HexaPro, Omicron BA.5 variant) in complex with CeSPIACE, class 2
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, CeSPIACE, Spike glycoprotein
Authors:	Suzuki, H, Nakamura, S, Fujiyoshi, Y.
Deposit date:	2024-02-21
Release date:	2025-01-15
Method:	ELECTRON MICROSCOPY (5.2 Å)
Cite:	Development of a short-peptide inhibiting any SARS-CoV-2 variants based on structural biology To Be Published

9CEC

SARS-CoV-2 3CL Protease complexed with covalent inhibitor BC671
Descriptor:	3C-like proteinase nsp5, DIMETHYL SULFOXIDE, N-[(2S)-1-{[(2S)-1-hydroxy-3-(2-oxo-1,2-dihydropyridin-3-yl)propan-2-yl]amino}-4-methyl-1-oxopentan-2-yl]-1H-indole-2-carboxamide
Authors:	Farzandh, S, Hoffpauir, Z.A, Meneely, K.M, Lamb, A.L.
Deposit date:	2024-06-26
Release date:	2025-01-15
Last modified:	2025-01-22
Method:	X-RAY DIFFRACTION (2.36 Å)
Cite:	Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents. J.Am.Chem.Soc., 147, 2025

9CED

SARS-CoV-2 3CL Protease complexed with covalent inhibitor VK13
Descriptor:	3C-like proteinase nsp5, N-[(2S)-1-{[(2S)-1-hydroxy-3-(2-oxo-1,2-dihydropyridin-3-yl)propan-2-yl]amino}-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide
Authors:	Hoffpauir, Z.A, Meneely, K.M, Lamb, A.L.
Deposit date:	2024-06-26
Release date:	2025-01-15
Last modified:	2025-01-22
Method:	X-RAY DIFFRACTION (1.82 Å)
Cite:	Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents. J.Am.Chem.Soc., 147, 2025

9CEK

SARS-CoV-2 3CL Protease complexed with covalent inhibitor VK20
Descriptor:	3C-like proteinase nsp5, L(+)-TARTARIC ACID, N-[(2S)-1-amino-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide, ...
Authors:	Hoffpauir, Z.A, Meneely, K.M, Lamb, A.L.
Deposit date:	2024-06-26
Release date:	2025-01-15
Last modified:	2025-01-22
Method:	X-RAY DIFFRACTION (1.38 Å)
Cite:	Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents. J.Am.Chem.Soc., 147, 2025

9CF9

SARS-CoV-2 3CL Protease complexed with covalent inhibitor BC787
Descriptor:	3C-like proteinase nsp5, N-[(2S)-1-{[(2S)-1-hydroxy-3-(pyridin-3-yl)propan-2-yl]amino}-4-methyl-1-oxopentan-2-yl]-4-methoxy-1H-indole-2-carboxamide
Authors:	Hoffpauir, Z.A, Meneely, K.M, Lamb, A.L.
Deposit date:	2024-06-27
Release date:	2025-01-15
Last modified:	2025-01-22
Method:	X-RAY DIFFRACTION (2 Å)
Cite:	Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents. J.Am.Chem.Soc., 147, 2025

9CFB

SARS-CoV-2 3CL Protease complexed with covalent inhibitor BC674
Descriptor:	3C-like proteinase nsp5, N-[(2S)-3-cyclohexyl-1-{[(2S)-1-hydroxy-3-(2-oxo-1,2-dihydropyridin-3-yl)propan-2-yl]amino}-1-oxopropan-2-yl]-1H-indole-2-carboxamide, SODIUM ION
Authors:	Hoffpauir, Z.A, Meneely, K.M, Lamb, A.L.
Deposit date:	2024-06-27
Release date:	2025-01-15
Last modified:	2025-01-22
Method:	X-RAY DIFFRACTION (1.45 Å)
Cite:	Dual Inhibitors of SARS-CoV-2 3CL Protease and Human Cathepsin L Containing Glutamine Isosteres Are Anti-CoV-2 Agents. J.Am.Chem.Soc., 147, 2025

9IUP

KP.3 RBD in complex with ACE2
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, Spike protein S1
Authors:	Feng, L.L.
Deposit date:	2024-07-22
Release date:	2025-01-15
Last modified:	2025-07-02
Method:	ELECTRON MICROSCOPY (3.3 Å)
Cite:	Structural and molecular basis of the epistasis effect in enhanced affinity between SARS-CoV-2 KP.3 and ACE2. Cell Discov, 10, 2024

9IUQ

KP.2 RBD in complex with ACE2
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, Spike protein S1
Authors:	Feng, L.L.
Deposit date:	2024-07-22
Release date:	2025-01-15
Last modified:	2025-06-25
Method:	ELECTRON MICROSCOPY (3.3 Å)
Cite:	Structural and molecular basis of the epistasis effect in enhanced affinity between SARS-CoV-2 KP.3 and ACE2. Cell Discov, 10, 2024

9IUU

JN.1 RBD with Q493E in complex with ACE2
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, Angiotensin-converting enzyme 2, CHLORIDE ION, ...
Authors:	Feng, L.L.
Deposit date:	2024-07-22
Release date:	2025-01-15
Last modified:	2025-07-02
Method:	ELECTRON MICROSCOPY (3.29 Å)
Cite:	Structural and molecular basis of the epistasis effect in enhanced affinity between SARS-CoV-2 KP.3 and ACE2. Cell Discov, 10, 2024

9JJ7

The crystal structure of SARS-CoV-2 NSP5 in complex with eIF4G2
Descriptor:	3C-like proteinase nsp5, Eukaryotic translation initiation factor 4 gamma 2
Authors:	Yan, X, Jin, Z, Wang, Y, Zhang, J.
Deposit date:	2024-09-13
Release date:	2025-01-15
Method:	X-RAY DIFFRACTION (1.8 Å)
Cite:	Coronavirus NSP5 is an Evolutionarily Conserved Inhibitor of Host Translation To Be Published

8XAL

Cryo-EM structure of SARS-CoV-2 S-BQ.1 in complex with ACE2
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Angiotensin-converting enzyme 2,Green fluorescent protein (Fragment), ...
Authors:	Hsu, H.F, Wu, M.H, Chang, Y.C, Hsu, S.T.D.
Deposit date:	2023-12-04
Release date:	2025-01-22
Last modified:	2025-07-02
Method:	ELECTRON MICROSCOPY (3.2 Å)
Cite:	Functional and structural investigation of a broadly neutralizing SARS-CoV-2 antibody. JCI Insight, 9, 2024

8XWR

Crystal structure of SARS-CoV-2 3CLpro-T21I/L50F double mutant with its peptidyl substrate
Descriptor:	3C-like proteinase nsp5, cleaved N-terminal product of nsp5/6 substrate peptide
Authors:	Zhang, L.J, Hu, Q.
Deposit date:	2024-01-16
Release date:	2025-01-22
Method:	X-RAY DIFFRACTION (1.7 Å)
Cite:	Crystal structure of SARS-CoV-2 3CLpro-T21I/L50F double mutant with its peptidyl substrate To Be Published

8XWT

Crystal structure of SARS-CoV-2 3CLpro-L50F mutant with its peptidyl substrate
Descriptor:	3C-like proteinase nsp5, CYS-SER-GLY-VAL-THR-PHE-GLN-SER-ALA-VAL-LYS-ARG-THR-ILE
Authors:	Zhang, L.J, Hu, Q.
Deposit date:	2024-01-16
Release date:	2025-01-22
Method:	X-RAY DIFFRACTION (1.7 Å)
Cite:	Crystal structure of SARS-CoV-2 3CLpro-L50F mutant with its peptidyl substrate To Be Published

8XY9

Crystal structure of SARS-CoV-2 BF.7 RBD and human ACE2 complex
Descriptor:	2-acetamido-2-deoxy-beta-D-glucopyranose, 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose, Processed angiotensin-converting enzyme 2, ...
Authors:	Lan, J, Wang, C.H.
Deposit date:	2024-01-19
Release date:	2025-01-22
Last modified:	2025-04-16
Method:	X-RAY DIFFRACTION (3.64 Å)
Cite:	Receptor binding mechanism and immune evasion capacity of SARS-CoV-2 BQ.1.1 lineage. Virology, 600, 2024

<181 182 183 184 185 186 187188189 190 191 192 193 194 195 196 >

Total results:	5197
Displayed results:	25
Sorted by:	Release date (from oldest)